AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
- Conditions
- Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)Drug: Placebo to match CK-4021586
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 60
- Registration Number
- NCT06793371
- Locations
- ๐บ๐ธ
DelRicht Research, Vienna, Virginia, United States
๐บ๐ธEastern Shore Research Institute, LLC, Fairhope, Alabama, United States
๐บ๐ธMorristown Medical Center, Morristown, New Jersey, United States
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
- Conditions
- Heart FailureHeart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Omecamtiv Mecarbil (OM)Drug: Placebo
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 1800
- Registration Number
- NCT06736574
- Locations
- ๐บ๐ธ
Advanced Cardiovascular, LLC, Alexander City, Alabama, United States
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธPima Heart and Vascular Clinical Research, Tucson, Arizona, United States
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
- Conditions
- PediatricSymptomatic Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 40
- Registration Number
- NCT06412666
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธUniversity of California, Los Angeles (UCLA), Los Angeles, California, United States
๐บ๐ธChildren's Hospital Colorado, Aurora, Colorado, United States
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
- Conditions
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 500
- Registration Number
- NCT06081894
- Locations
- ๐ฆ๐ท
Hospital Italiano de Buenos Aires Juan Domingo Peron, Buenos Aires, Argentina
๐ฆ๐บFiona Stanley Hospital, AHF Unit, Murdoch, Australia
๐ง๐ทInstituto D'Or de Pesquisa e Ensino/Cardio Pulmonar da Bahia SA, Ondina, Salvador, Brazil
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 44
- Registration Number
- NCT05924815
- Locations
- ๐บ๐ธ
Celerion, Inc 2420, Tempe, Arizona, United States
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Placebo for CK-4021586
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 102
- Registration Number
- NCT05877053
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 170
- Registration Number
- NCT05767346
- Locations
- ๐บ๐ธ
Alaska Heart and Vascular Institute, Anchorage, Alaska, United States
๐บ๐ธMayo Clinic, Phoenix, Arizona, United States
๐บ๐ธUC San Diego Health - Sulpizio Cardiovascular Center, La Jolla, California, United States
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Placebo for CK-3828136
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 57
- Registration Number
- NCT05662215
- Locations
- ๐บ๐ธ
Labcorp Clinical Research Unit Inc., Dallas, Texas, United States
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 71
- Registration Number
- NCT05442775
- Locations
- ๐บ๐ธ
St. Joseph's Hospital & Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States
๐บ๐ธUniversity of California Irvine - ALS & Neuromuscular Center, Orange, California, United States
๐บ๐ธCalifornia Pacific Medical Center - Forbes Norris MDA/ALS Research Center, San Francisco, California, United States
Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM)
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)Drug: Placebo to match aficamten
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 282
- Registration Number
- NCT05186818
- Locations
- ๐บ๐ธ
Alaska Heart and Vascular Institute, Anchorage, Alaska, United States
๐บ๐ธUC San Diego Health - Sulpizio Cardiovascular Center, La Jolla, California, United States
๐บ๐ธCedars-Sinai Medical Center - Smidt Heart Institute Clinic, Los Angeles, California, United States